106 related articles for article (PubMed ID: 19138929)
1. Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention.
Lance P; Hamilton SR
Cancer Prev Res (Phila); 2008 Jun; 1(1):4-8. PubMed ID: 19138929
[No Abstract] [Full Text] [Related]
2. Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
Stevens RG; Pretlow TP; Hurlstone DP; Giardina C; Rosenberg DW
Cancer Prev Res (Phila); 2008 Aug; 1(3):215-6; author reply 216. PubMed ID: 19138959
[No Abstract] [Full Text] [Related]
3. Early events in human colorectal carcinogenesis. Aberrant crypts and microadenoma.
Roncucci L
Ital J Gastroenterol; 1992; 24(9):498-501. PubMed ID: 1489980
[TBL] [Abstract][Full Text] [Related]
4. Screening for colorectal cancer: does it all start with aberrant crypt foci?
Rasheed S; Rigas B
Gastrointest Endosc; 2008 Jun; 67(7):1103-5. PubMed ID: 18513552
[No Abstract] [Full Text] [Related]
5. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
Hurlstone DP; Karajeh M; Sanders DS; Drew SK; Cross SS
Am J Gastroenterol; 2005 Jun; 100(6):1283-9. PubMed ID: 15929758
[TBL] [Abstract][Full Text] [Related]
6. Chemopreventive effects of dietary folate on intestinal polyps in Apc+/-Msh2-/- mice.
Song J; Sohn KJ; Medline A; Ash C; Gallinger S; Kim YI
Cancer Res; 2000 Jun; 60(12):3191-9. PubMed ID: 10866310
[TBL] [Abstract][Full Text] [Related]
7. Aberrant crypt foci in the adenoma prevention with celecoxib trial.
Cho NL; Redston M; Zauber AG; Carothers AM; Hornick J; Wilton A; Sontag S; Nishioka N; Giardiello FM; Saltzman JR; Gostout C; Eagle CJ; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2008 Jun; 1(1):21-31. PubMed ID: 19138933
[TBL] [Abstract][Full Text] [Related]
8. Do serrated adenomas have higher malignant potential than traditional adenomas?
Zou B; Wong BC
J Gastroenterol Hepatol; 2007 Nov; 22(11):1701-3. PubMed ID: 17914936
[No Abstract] [Full Text] [Related]
9. Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer.
Stevens RG; Swede H; Heinen CD; Jablonski M; Grupka M; Ross B; Parente M; Tirnauer JS; Giardina C; Rajan TV; Rosenberg DW; Levine J
Cancer Lett; 2007 Apr; 248(2):262-8. PubMed ID: 16950561
[TBL] [Abstract][Full Text] [Related]
10. Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis.
Mori H; Yamada Y; Kuno T; Hirose Y
Mutat Res; 2004 May; 566(3):191-208. PubMed ID: 15082237
[TBL] [Abstract][Full Text] [Related]
11. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
12. Importance of serrated polyps in colorectal carcinogenesis.
Liang JJ; Bissett I; Kalady M; Bennet A; Church JM
ANZ J Surg; 2013 May; 83(5):325-30. PubMed ID: 23078414
[TBL] [Abstract][Full Text] [Related]
13. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Gupta AK; Schoen RE
Curr Opin Gastroenterol; 2009 Jan; 25(1):59-65. PubMed ID: 19114775
[TBL] [Abstract][Full Text] [Related]
14. Endoscopic identification and quantification of aberrant crypt foci in the human colon.
Adler DG; Gostout CJ; Sorbi D; Burgart LJ; Wang L; Harmsen WS
Gastrointest Endosc; 2002 Nov; 56(5):657-62. PubMed ID: 12397272
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis in the colonic crypt, colorectal adenomata, and manipulation by chemoprevention.
West NJ; Courtney ED; Poullis AP; Leicester RJ
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1680-7. PubMed ID: 19505899
[TBL] [Abstract][Full Text] [Related]
16. The natural history of aberrant crypt foci.
Schoen RE; Mutch M; Rall C; Dry SM; Seligson D; Umar A; Pinsky P
Gastrointest Endosc; 2008 Jun; 67(7):1097-102. PubMed ID: 18178205
[TBL] [Abstract][Full Text] [Related]
17. Intermediate effect markers for colorectal cancer.
Baron JA
IARC Sci Publ; 2001; 154():113-29. PubMed ID: 11220651
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of colorectal cancer.
Niitsu Y; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Abe T; Kogawa T; Takahashi M; Matsunaga T; Kato J
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S40-3. PubMed ID: 15309513
[TBL] [Abstract][Full Text] [Related]
19. Serrated adenoma and colorectal cancer.
Jass JR
J Pathol; 1999 Apr; 187(5):499-502. PubMed ID: 10398112
[TBL] [Abstract][Full Text] [Related]
20. Comparison of malignant potential between serrated adenomas and traditional adenomas.
Song SY; Kim YH; Yu MK; Kim JH; Lee JM; Son HJ; Rhee PL; Kim JJ; Paik SW; Rhee JC
J Gastroenterol Hepatol; 2007 Nov; 22(11):1786-90. PubMed ID: 17914951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
